一种新的PET扫描剂在发现肾癌,特别是小肿瘤方面显示出很高的准确性,现已在全球准则中推荐。 A new PET scan agent shows high accuracy in detecting kidney cancer, especially small tumors, and is now recommended in global guidelines.

TLX250-CDx(Zircaix)是调查性的PET成像剂,针对肾癌中的碳己酰九,首次列入全球主要核医学组织的新准则。 TLX250-CDx (Zircaix), an investigational PET imaging agent targeting carbonic anhydrase IX in kidney cancer, has been included in new guidelines from major global nuclear medicine organizations for the first time. 准则强调了它在发现清晰细胞肾脏细胞癌方面的高度准确性,在ZIRCON试验中具有86%的灵敏度、87%的特性和93%的正预测值,特别是对于小型、难以看得见的肿瘤。 The guidelines highlight its high accuracy in detecting clear cell renal cell carcinoma, with 86% sensitivity, 87% specificity, and 93% positive predictive value in the ZIRCON trial, particularly for small, hard-to-see tumors. 与标准的18FF-FDG PET不同,由于肾脏排泄量较低,其图像清晰度更好。 Unlike standard 18F-FDG PET, it offers better image clarity due to lower kidney excretion. 该制剂尚未得到批准,但可以加速临床使用,作为精确诊断和个性化治疗规划的工具。 The agent is not yet approved but may accelerate clinical use as a tool for precise diagnosis and personalized treatment planning.